FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Högberg

Research Profile

Concepts & Ideas

Structure-Activity Relationship

Chemicals & Drugs

Living Beings

Co-author Network

Publications

TOP 3
Sanjita Sasmal; V J Sebastian; Dhanya Shashikumar; V Sihorkar; Manvendra P Singh; Gujjary Srinivas; Juluri Suresh; Rashmi Talwar; Oystein Rist; Chandrasekhar Abbineni; Gade Balaji; D Balasubrahmanyam; Srisailam Cheera; Lisbeth Elster; Thomas M Frimurer; K Harinder Reddy; Vikram P Jadhav; Hariprasada R Kanna Reddy; Ish Khanna; Pradip K Sasmal; Thomas Högberg
Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: part 2.
Sanjita Sasmal; V J Sebastian; Dhanya Shashikumar; Gujjary Srinivas; Juluri Suresh; Rashmi Talwar; Oystein Rist; Gade Balaji; D Balasubrahmanyam; Lisbeth Elster; Thomas M Frimurer; K Harinder Reddy; Vikram P Jadhav; Hariprasada R Kanna Reddy; Ish Khanna; Shivakumar Kyasa; Syed Muzeeb; Pradip K Sasmal; Thomas Högberg
Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists.
Pradip K Sasmal; Sanjita Sasmal; P Tirumala Rao; B Venkatesham; M Roshaiah; Chandrasekhar Abbineni; Ish Khanna; Vikram P Jadhav; J Suresh; Rashmi Talwar; Syed Muzeeb; Jean-Marie Receveur; Thomas M Frimurer; Øystein Rist; Lisbeth Elster; Thomas Högberg
Discovery of novel, orally available benzimidazoles as melanin concentrating hormone receptor 1 (MCHR1) antagonists.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Högberg (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Sanjita Sasmal; V J Sebastian; Dhanya Shashikumar; V Sihorkar; Manvendra P Singh; Gujjary Srinivas; Juluri Suresh; Rashmi Talwar; Oystein Rist; Chandrasekhar Abbineni; Gade Balaji; D Balasubrahmanyam; Srisailam Cheera; Lisbeth Elster; Thomas M Frimurer; K Harinder Reddy; Vikram P Jadhav; Hariprasada R Kanna Reddy; Ish Khanna; Pradip K Sasmal; Thomas Högberg
Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: part 2.
Bioorganic & medicinal chemistry letters 2012;22(9):3163-7.
2012: Sanjita Sasmal; V J Sebastian; Dhanya Shashikumar; Gujjary Srinivas; Juluri Suresh; Rashmi Talwar; Oystein Rist; Gade Balaji; D Balasubrahmanyam; Lisbeth Elster; Thomas M Frimurer; K Harinder Reddy; Vikram P Jadhav; Hariprasada R Kanna Reddy; Ish Khanna; Shivakumar Kyasa; Syed Muzeeb; Pradip K Sasmal; Thomas Högberg
Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists.
Bioorganic & medicinal chemistry letters 2012;22(9):3157-62.
2010: Pradip K Sasmal; Sanjita Sasmal; P Tirumala Rao; B Venkatesham; M Roshaiah; Chandrasekhar Abbineni; Ish Khanna; Vikram P Jadhav; J Suresh; Rashmi Talwar; Syed Muzeeb; Jean-Marie Receveur; Thomas M Frimurer; Øystein Rist; Lisbeth Elster; Thomas Högberg
Discovery of novel, orally available benzimidazoles as melanin concentrating hormone receptor 1 (MCHR1) antagonists.
Bioorganic & medicinal chemistry letters 2010;20(18):5443-8.
2010: Marie Grimstrup; Jean-Marie Receveur; Øystein Rist; Thomas M Frimurer; Peter Aadal Nielsen; Jesper M Mathiesen; Thomas Högberg
Exploration of SAR features by modifications of thiazoleacetic acids as CRTH2 antagonists.
Bioorganic & medicinal chemistry letters 2010;20(5):1638-41.
2010: Øystein Rist; Marie Grimstrup; Jean-Marie Receveur; Thomas M Frimurer; Trond Ulven; Evi Kostenis; Thomas Högberg
Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 1.
Bioorganic & medicinal chemistry letters 2010;20(3):1177-80.
2010: Marie Grimstrup; Øystein Rist; Jean-Marie Receveur; Thomas M Frimurer; Trond Ulven; Jesper M Mathiesen; Evi Kostenis; Thomas Högberg
Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 2.
Bioorganic & medicinal chemistry letters 2010;20(3):1181-5.
2010: Jean-Marie Receveur; Anthony Murray; Jean-Michel Linget; Pia K Nørregaard; Martin Cooper; Emelie Bjurling; Peter Aadal Nielsen; Thomas Högberg
Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier.
Bioorganic & medicinal chemistry letters 2010;20(2):453-7.
2010: Martin Cooper; Jean-Marie Receveur; Emelie Bjurling; Pia K Nørregaard; Peter Aadal Nielsen; Niklas Sköld; Thomas Högberg
Exploring SAR features in diverse library of 4-cyanomethyl-pyrazole-3-carboxamides suitable for further elaborations as CB1 antagonists.
Bioorganic & medicinal chemistry letters 2010;20(1):26-30.
2007: Lena Uller; Jesper Mosolff Mathiesen; Lisa Alenmyr; Magnus Korsgren; Trond Ulven; Thomas Högberg; Gunnar Andersson; Carl G A Persson; Evi Kostenis
Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation.
Respiratory research 2007;8():16.
2006: Trond Ulven; Jean-Marie Receveur; Marie Grimstrup; Øystein Rist; Thomas M Frimurer; Lars-Ole Gerlach; Jesper Mosolff Mathiesen; Evi Kostenis; Lena Uller; Thomas Högberg
Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits.
Journal of medicinal chemistry 2006;49(23):6638-41.
2006: Trond Ulven; Paul Little; Jean-Marie Receveur; Thomas M Frimurer; Oystein Rist; Pia K Nørregaard; Thomas Högberg
6-Acylamino-2-amino-4-methylquinolines as potent melanin-concentrating hormone 1 receptor antagonists: structure-activity exploration of eastern and western parts.
Bioorganic & medicinal chemistry letters 2006;16(4):1070-5.
2005: Trond Ulven; Thomas M Frimurer; Jean-Marie Receveur; Paul Little; Oystein Rist; Pia K Nørregaard; Thomas Högberg
6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode.
Journal of medicinal chemistry 2005;48(18):5684-97.
2005: Thomas M Frimurer; Trond Ulven; Christian E Elling; Lars-Ole Gerlach; Evi Kostenis; Thomas Högberg
A physicogenetic method to assign ligand-binding relationships between 7TM receptors.
Bioorganic & medicinal chemistry letters 2005;15(16):3707-12.
2005: Thomas Högberg
Widening bottlenecks in drug discovery: glimpses from Drug Discovery Technology Europe 2005.
Drug discovery today 2005;10(12):820-2.
2004: Jean-Marie Receveur; Emelie Bjurling; Trond Ulven; Paul Little; Pia K Nørregaard; Thomas Högberg
4-Acylamino-and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists.
Bioorganic & medicinal chemistry letters 2004;14(20):5075-80.
2003: Sylvain Clavier; Oystein Rist; Stina Hansen; Lars-Ole Gerlach; Thomas Högberg; Jan Bergman
Preparation and evaluation of sulfur-containing metal chelators.
Organic & biomolecular chemistry 2003;1(23):4248-53.
1995: Christer Halldin; Lars Farde; Thomas Högberg; Nina Mohell; Håkan Hall; T Suhara; Per Karlsson; Y Nakashima; Carl-Gunnar Swahn
Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1995;36(7):1275-81.
1994: Christer Halldin; Thomas Högberg; Lars Farde
Fluorine-18-labelled NCQ 115, a selective dopamine D-2 receptor ligand. Preparation and positron emission tomography.
Nuclear medicine and biology 1994;21(4):627-31.
1993: Nina Mohell; M Sällemark; S Rosqvist; Asa Malmberg; Thomas Högberg; DM Jackson
Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors.
European journal of pharmacology 1993;238(1):121-5.
1993: Inge T Christensen; Flemming Steen Jørgensen; L A Svensson; Thomas Högberg
Three-dimensional structures of human phospholipase A2 from pancreas and synovial fluid by model building.
Drug design and discovery 1993;10(2):101-13.
1993: R S Tsai; Pierre-Alain Carrupt; Bernard Testa; P Gaillard; N el Tayar; Thomas Högberg
Effects of solvation on the ionization and conformation of raclopride and other antidopaminergic 6-methoxysalicylamides: insight into the pharmacophore.
Journal of medicinal chemistry 1993;36(2):196-204.
1993: Thomas Högberg
The development of dopamine D2-receptor selective antagonists.
Drug design and discovery 1993;9(3-4):333-50.
1992: J O Marcusson; U Norinder; Thomas Högberg; S B Ross
Inhibition of [3H]paroxetine binding by various serotonin uptake inhibitors: structure-activity relationships.
European journal of pharmacology 1992;215(2-3):191-8.
1992: U Norinder; Thomas Högberg
PLS-based quantitative structure-activity relationship for substituted benzamides of clebopride type. Application of experimental design in drug design.
Acta chemica Scandinavica (Copenhagen, Denmark : 1989) 1992;46(4):363-6.
1992: Håkan Hall; Lars Farde; Christer Halldin; Thomas Högberg; S Larsson; Göran C Sedvall
Imaging of dopamine receptors using PET and SPECT.
Neurochemistry international 1992;20 Suppl():329S-333S.
1992: U Norinder; Thomas Högberg
A quantitative structure-activity relationship for some dopamine D2 antagonists of benzamide type.
Acta pharmaceutica Nordica 1992;4(2):73-8.
1992: I Csöregh; Thomas Högberg
Molecular and crystal structure of the hydrochloride monohydrate of (R)-N-[[1-(4-fluorobenzyl)-2-pyrrolidinyl]methyl]-5-bromo-2,3- dimethoxybenzamide, NCQ 115, a novel dopamine D2 receptor antagonist.
Acta pharmaceutica Nordica 1992;4(1):1-4.
1991: Håkan Hall; Thomas Högberg; Christer Halldin; S Bengtsson; I Wedel
Synthesis and binding properties of the fluorinated substituted benzamide [3H]NCQ 115, a new selective dopamine D2 receptor ligand.
European journal of pharmacology 1991;201(1):1-10.
1991: C Köhler; H Ericson; Thomas Högberg; Christer Halldin; V Chan-Palay
Dopamine D2 receptors in the rat, monkey and the post-mortem human hippocampus. An autoradiographic study using the novel D2-selective ligand 125I-NCQ 298.
Neuroscience letters 1991;125(1):12-4.
1991: Thomas Högberg; P Ström; T de Paulis; B Stensland; I Csöregh; K Lundin; Håkan Hall; S O Ogren
Potential antipsychotic agents. 9. Synthesis and stereoselective dopamine D-2 receptor blockade of a potent class of substituted (R)-N-[(1-benzyl-2-pyrrolidinyl)methyl]benzamides. Relations to other side chain congeners.
Journal of medicinal chemistry 1991;34(3):948-55.
1991: Christer Halldin; Lars Farde; Thomas Högberg; Håkan Hall; P Ström; A Ohlberger; O Solin
A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1991;18(8):871-81.
1991: Håkan Hall; Thomas Högberg; Christer Halldin; C Köhler; P Ström; S B Ross; S A Larsson; Lars Farde
NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D2 receptors.
Psychopharmacology 1991;103(1):6-18.
1991: Christer Halldin; Lars Farde; Håkan Hall; Thomas Högberg; G Printz; W Pulka; Göran C Sedvall; O Solin
Synthesis of five benzamide analogs. Comparison with positron emission tomography.
Acta radiologica. Supplementum 1991;376():121-2.
1990: J R Cashman; Z C Yang; Thomas Högberg
Oxidation of N-hydroxynorzimeldine to a stable nitrone by hepatic monooxygenases.
Chemical research in toxicology 1990;3(5):428-32.
1990: Thomas Högberg; T de Paulis; L Johansson; Y Kumar; Håkan Hall; S O Ogren
Potential antipsychotic agents. 7. Synthesis and antidopaminergic properties of the atypical highly potent (S)-5-bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide and related compounds. A comparative study.
Journal of medicinal chemistry 1990;33(8):2305-9.
1990: Thomas Högberg; S Bengtsson; T de Paulis; L Johansson; P Ström; Håkan Hall; S O Ogren
Potential antipsychotic agents 5. Synthesis and antidopaminergic properties of substituted 5,6-dimethoxysalicylamides and related compounds.
Journal of medicinal chemistry 1990;33(4):1155-63.
1990: Christer Halldin; Lars Farde; Thomas Högberg; Håkan Hall; G Sedvall
Carbon-11 labelling of eticlopride in two different positions--a selective high-affinity ligand for the study of dopamine D-2 receptors using PET.
International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes 1990;41(7):669-74.
1990: C Thomas; W Lippe; Thomas Högberg; Willem Seinen; Nanne Bloksma
Induction of popliteal lymph node enlargement and antibody production in the mouse by pyridylallylamines related to zimeldine.
International journal of immunopharmacology 1990;12(5):569-76.
1990: C Thomas; Peter J Punt; R Warringa; Thomas Högberg; Willem Seinen; Nanne Bloksma
Popliteal lymph node enlargement and antibody production in the mouse induced by zimeldine and related compounds with varying side chains.
International journal of immunopharmacology 1990;12(5):561-8.
1990: Thomas Högberg; P Ström; Håkan Hall; C Köhler; Christer Halldin; Lars Farde
Syntheses of [123I]-, [125I]- and unlabelled (S)-3-iodo-5,6-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]salicylamide (NCQ 298), selective ligands for the study of dopamine D-2 receptors.
Acta pharmaceutica Nordica 1990;2(1):53-60.
1989: L Gawell; C E Hagberg; Thomas Högberg; M Widman
Synthesis of 5-substituted 5-hydroxy-2-pyrrolidones, metabolites of the antipsychotic benzamide remoxipride.
Acta chemica Scandinavica (Copenhagen, Denmark : 1989) 1989;43(5):476-80.
1989: U Norinder; Thomas Högberg
QSAR on substituted salicylamides.
Progress in clinical and biological research 1989;291():369-72.
1988: J R Cashman; J Proudfoot; D W Pate; Thomas Högberg
Stereoselective N-oxygenation of zimeldine and homozimeldine by the flavin-containing monooxygenase.
Drug metabolism and disposition: the biological fate of chemicals 1988;16(4):616-22.
1988: Thomas Högberg; S B Ross; P Ström; Gary L Grunewald; M W Creese; J D Bunce
Homoallylic amines related to zimeldine. A comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis.
Journal of medicinal chemistry 1988;31(5):913-9.
1988: Lars Farde; Stefan Pauli; Håkan Hall; L Eriksson; Christer Halldin; Thomas Högberg; L Nilsson; I Sjögren; Sharon Stone-Elander
Stereoselective binding of 11C-raclopride in living human brain--a search for extrastriatal central D2-dopamine receptors by PET.
Psychopharmacology 1988;94(4):471-8.
1987: Thomas Högberg; U Norinder; S Rämsby; B Stensland
Crystallographic, theoretical and molecular modelling studies on the conformations of the salicylamide, raclopride, a selective dopamine-D2 antagonist.
The Journal of pharmacy and pharmacology 1987;39(10):787-96.
1987: S Gronowitz; C Westerlund; Thomas Högberg; S Rämsby; Håkan Hall; U H Lindberg
Synthetic and receptor binding studies on bicyclic annelated systems related to cyproheptadine.
Acta pharmaceutica Suecica 1987;24(1):1-14.
1987: Thomas Högberg; S Rämsby; S O Ogren; U Norinder
New selective dopamine D-2 antagonists as antipsychotic agents. Pharmacological, chemical, structural and theoretical considerations.
Acta pharmaceutica Suecica 1987;24(6):289-328.
1986: Thomas Högberg; S Rämsby; T de Paulis; B Stensland; I Csöregh; A Wägner
Solid state conformations and antidopaminergic effects of remoxipride hydrochloride and a closely related salicylamide, FLA 797, in relation to dopamine receptor models.
Molecular pharmacology 1986;30(4):345-51.
1985: Thomas Högberg; J Lundström; B Ulff
Synthesis and spectroscopic characterization of pyridyl N-oxidized zimeldine metabolites.
Acta pharmaceutica Suecica 1985;22(3):123-30.
1984: Lester A Mitscher; Thomas Högberg; S D Drake; A W Burgstahler; M Jackson; B Lee; R I Sheldon; H E Gracey; W Kohl; R J Theriault
Isolation and structural determination of siderochelin C, a fermentation product of an unusual Actinomycetes sp.
The Journal of antibiotics 1984;37(10):1260-3.
1984: Thomas Högberg; I Khanna; S D Drake; Lester A Mitscher; Linus L Shen
Structure-activity relationships among DNA gyrase inhibitors. Synthesis and biological evaluation of 1,2-dihydro-4, 4-dimethyl-1-oxo-2-naphthalenecarboxylic acids as 1-carba bioisosteres of oxolinic acid.
Journal of medicinal chemistry 1984;27(3):306-10.
1984: Thomas Högberg; M Vora; S D Drake; Lester A Mitscher; Daniel T Chu
Structure-activity relationships among DNA-gyrase inhibitors. Synthesis and antimicrobial evaluation of chromones and coumarins related to oxolinic acid.
Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry 1984;38(5):359-66.
1983: Lester A Mitscher; J K Swayze; Thomas Högberg; I Khanna; G S Rao; R J Theriault; W Kohl; C Hanson; R Egan
Biosynthesis of cetocycline.
The Journal of antibiotics 1983;36(10):1405-7.
1981: Thomas Högberg; B Ulff; A L Renyi; S B Ross
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
Journal of medicinal chemistry 1981;24(12):1499-507.
1981: J Lundström; Thomas Högberg; T Gosztonyi; T de Paulis
Metabolism of zimelidine in rat, dog and man. Identification and synthesis of the principal metabolites.
Arzneimittel-Forschung 1981;31(3):486-94.
1979: K Högberg; J E Lindgren; Thomas Högberg; B Ulff
Simultaneous GLC determination of zimelidine and norzimelidine. Synthesis of secondary amines as closely related internal standards.
Acta pharmaceutica Suecica 1979;16(5):299-308.
1977: Thomas Högberg; G Bondesson; N E Stjernström
Potential hypolipidemic agents. XVII. Synthesis and plasma lipid-lowering properties of compounds related to ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate and ethyl 2-(4-chlorophenoxy)-2-methylpropionate.
Acta pharmaceutica Suecica 1977;14(2):149-60.
1977: Thomas Högberg; G Bondesson; A Misiorny; N E Stjernström
Potential hypolipidemic agents. XVI. Synthesis and plasma lipid-lowering properties of alpha-substituted ethyl 4-dibenzofuranyloxyacetates and ethyl 4-chlorophenoxyacetates. A comparative study.
Acta pharmaceutica Suecica 1977;14(2):137-48.
1976: Thomas Högberg; G Bondesson; A Misiorny; N E Stjernström
Potential hypolipidemic agents. XV Synthesis and plasma lipid-lowering properties of derivatives of 2-phenoxy-2-methylpropionic acid.
Acta pharmaceutica Suecica 1976;13(5-6):427-38.
1976: G Bondesson; Thomas Högberg; A Misiorny; N E Stjernström
Potential hypolipidemic agents. XIV. Synthesis and plasma lipid-lowering properties of substituted biphenyls, diphenyl ethers and benzofurans related to ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate.
Acta pharmaceutica Suecica 1976;13(2):97-106.
1975: G Bondesson; Thomas Högberg; O Magnusson; N E Stjernström
Potential hypolipidemic agents. XI. Synthesis, plasma lipid-lowering properties and bioavailability of some esters of 2-(4-dibenzofuranoloxy)-2-methylpropionic acid.
Acta pharmaceutica Suecica 1975;12(4):361-74.
1974: G Bondesson; C Hedbom; Thomas Högberg; O Magnusson; N E Stjernström; L A Carlson
Potential hypolipidemic agents. 7. Synthesis and lipid-lowering properties of 2-(dibenzofuranyloxy)-2-methylpropionates and related compounds.
Journal of medicinal chemistry 1974;17(1):108-12.